Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement

Reuters

06/19

Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement

Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2544166075"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544166075\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544166075?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-19 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544166075","market":"nz","top_or_hot":-1,"title":"Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-19 19:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1232","symbol_name":"複合型公用事業","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL7kd4mX:1","article_id":"2544166075","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544166075","pubTimestamp":1750332486,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for inform","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1232":"复合型公用事业","BK0188":"融资融券","002393":"力生制药","BK0028":"国家队","00882":"天津发展","BK0239":"医药制造"},"translate_title":"天津发展控股子公司力生制药与兴业银行新协议扩大投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002393":0.9,"00882":0.9},"content_text":"Lisheng Pharmaceutical, a Tianjin Development Holdings Subsidiary, Expands Investment with New Industrial Bank Agreement\n    \n\n        Lisheng Pharmaceutical, an indirect non-wholly owned subsidiary of Tianjin Development Holdings Limited, continues to play a significant role in the pharmaceutical industry in China. Primarily engaged in the manufacturing and sale of chemical drugs, Lisheng Pharmaceutical is a joint stock limited company in the People's Republic of China. The company benefits from a strategic relationship with Tianjin Development Holdings, which holds an effective interest of approximately 34.11% in Lisheng Pharmaceutical's issued share capital. This partnership aligns with Tianjin Development Holdings' broader investment strategy, which includes various sectors such as hotels, electrical and mechanical manufacturing, and strategic investments in port services and elevator and escalator production.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tianjin Development Holdings Limited published the original content used to generate this news brief on June 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}